World Pharma News Digest - 03.03.2008

World Pharma News Digest - 03.03.2008

Pfizer to Acquire Serenex to Extend Oncology Pipeline
Pfizer Inc today announced that it has entered into an agreement to
acquire Serenex, Inc., a privately-held biotechnology company with a
Phase I clinical candidate and an extensive compound library that
targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight
against cancer.
Read more...
* w w w .worldpharmanews . com /content/view/318/1/

Pharmathen's new Research and Development Centre in Pallini, Athens
Pharmathen S.A announced the establishment of a new Research and
Development Centre in Pallini, Athens. The new Research Centre will
focus on developing Generic molecules and is expected to significantly
reinforce Pharmathen's already excellent R&D capabilities. Pharmathen
is one of the strongest generic developer in Europe and with the
operation of the new facility the company's R&D activities will be
further increased.
Read more...
* w w w .worldpharmanews . com /content/view/317/1/

Update on GSK's malaria treatments: Dacart and Lapdap
Malaria is a devastating disease killing over one million people,
mostly young children and pregnant women every year. There is an
urgent need for new medicines to treat the disease as resistance
builds to older treatments. GSK and Medicines for Malaria Venture
(MMV) are working in partnerships on a number of projects dedicated to
finding new malaria treatments.
Read more...
* w w w .worldpharmanews . com /content/view/316/1/

Johnson & Johnson Diabetes Institute To Provide Education, Training to
Health Professionals
With mounting evidence that many health professionals lack the
training and skills to combat the nation's growing epidemic of
diabetes, the Johnson & Johnson Diabetes Institute, LLC opened its
first training center in the U.S. to improve how practitioners deliver
diabetes care in local communities.
Read more...
* w w w .worldpharmanews . com /content/view/315/1/

Forest Laboratories, Inc. Announces Amendment to Bystolic(TM)
(nebivolol) Agreement
Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of
Forest Laboratories, Inc. (NYSE: FRX), announced that it and Mylan
Inc. (NYSE: MYL) have amended their January 2006 agreement to
commercialize, develop and distribute the novel beta blocker
Bystolic(TM) (nebivolol), which is currently approved in the United
States for the treatment of hypertension.
Read more...
* w w w .worldpharmanews . com /content/view/314/1/

World Pharma News . net / Published News:

alliConnect - GlaxoSmithKline's official product blog
* w w w .worldpharmanews . net /Blogs/alliConnect - GlaxoSmithKlines official product blog/

The best pharma blogs, according to Pharmafocus Corroxannaa4s Weblog
* w w w .worldpharmanews . net /Blogs/The best pharma blogs according to Pharmafocus %AB Corroxannarsquos Weblog/

ADRs in Focus: Novartis ADRs decline - MSNBC Wire Services
* w w w .worldpharmanews . net /Financial/ADRs in Focus Novartis ADRs decline - MSNBC Wire Services/

Enough with the China Bashing Already: Bio Job Blog
* w w w .worldpharmanews . net /Blogs/Enough with the China Bashing Already Bio Job Blog-1/

CNTO411 Inaugural Blog Posting
* w w w .worldpharmanews . net /Blogs/CNTO411 - Inaugural Blog Posting/

Pharmalot Centocora4s 411: The Drugmaker Launches A Blog
* w w w .worldpharmanews . net /Blogs/Pharmalot - Centocorrsquos 411 The Drugmaker Launches A Blog/

Johnson & Johnson Diabetes Institute To Provide Education, Training to
Health Professionals
* w w w .worldpharmanews . net /Corporate/Johnson Johnson Diabetes Institute To Provide Education Training to Health Professionals/

Pharmalot Click Here: TV Drug Ads And Side Effect Reports
* w w w .worldpharmanews . net /Blogs/Pharmalot - Click Here TV Drug Ads And Side Effect Reports/

Wyeth discontinues Solvay partnership
* w w w .worldpharmanews . net /Corporate/Wyeth discontinues Solvay partnership/

DocTrain Life Sciences 2008 - Indianapolis, IN, June 23-26, 2008
* w w w .worldpharmanews . net /Conferences Events/DocTrain Life Sciences 2008 - Indianapolis IN June 23-26 2008/